Sildenafil improves exercise capacity in patients with cystic fibrosis: a proof-of-concept clinical trial

• Main Authors: Paula Rodriguez-Miguelez (Author), Haruki Ishii (Author), Nichole Seigler (Author), Reva Crandall (Author), Jeffrey Thomas (Author), Caralee Forseen (Author), Kathleen T. McKie (Author), Ryan A. Harris (Author)
• Formato: Libro
• Publicado: SAGE Publishing, 2019-11-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Background: Exercise intolerance is a common phenotype observed in patients with cystic fibrosis (CF). Treatment with sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, has previously been shown to improve exercise capacity (VO 2 peak) in other patient populations. Thus, the present study soug...